CYTOPATH BIOPSY LAB INC

Cytopath Biopsy Lab, Inc. specializes in advanced molecular diagnostics for thyroid cancer detection, primarily delivering the ThyroSeq V3 Genomic Classifier test to support clinical decision-making in surgical oncology. The company provides precision pathology services that analyze thyroid nodule specimens using next-generation sequencing to determine malignancy risk, enabling clinicians to avoid unnecessary thyroidectomies. Their technical expertise lies in in vitro diagnostic assays, genomic data interpretation, and cytology-based cancer classification, with a focused application in thyroid pathology. Cytopath Biopsy Lab’s differentiation stems from its exclusive deployment of ThyroSeq technology, a clinically validated genomic classifier that integrates mutational and gene expression profiling to deliver high-sensitivity, high-specificity results for indeterminate thyroid nodules. The contractor maintains a deep, sustained relationship with the Department of Veterans Affairs, consistently providing genomic thyroid testing services across multiple task orders. These engagements reflect a trusted, repeat procurement pattern centered on precision diagnostics for veteran patients with thyroid nodules, indicating strong alignment with VA’s mission to deliver evidence-based, cost-effective cancer care. The single award to the 250-NETWORK Contract Office 10 further confirms integration into VA’s centralized contracting infrastructure. Cytopath Biopsy Lab operates primarily under NAICS 621511 (Medical Laboratories), with secondary activity in 541380 (Testing Laboratories and Services), reflecting its role as a diagnostic service provider rather than a manufacturing entity. Its market positioning is niche but critical—serving as a specialized laboratory partner for oncology-focused healthcare systems requiring genomic validation in thyroid pathology. As a small business entity headquartered in Rye Brook, New York, Cytopath Biopsy Lab, Inc. is structured as a 2L (small business, non-manufacturer) with no federal certifications on record. Its geographic presence is centered in the Northeast, with operations tailored to federal healthcare delivery networks, particularly those serving veteran populations.